Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN)

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F13%3A%230000710" target="_blank" >RIV/00064190:_____/13:#0000710 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.eururo.2013.03.031" target="_blank" >http://dx.doi.org/10.1016/j.eururo.2013.03.031</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.eururo.2013.03.031" target="_blank" >10.1016/j.eururo.2013.03.031</a>

Result language
angličtina
Original language name
Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN)
Original language description
Storage symptoms are often undertreated in men with lower urinary tract symptoms (LUTS). Objective: To evaluate the combination of an antimuscarinic (solifenacin) with an alpha-blocker (tamsulosin) versus tamsulosin alone in the treatment of men with LUTS. Design, setting, and participants: A double-blind, 12-wk, phase 2 study in 937 men with LUTS (>= 3 mo, total International Prostate Symptom Score [IPSS] >= 13, and maximum urinary flow rate 4.0-15.0 ml/s). Intervention: Eight treatment groups: tamsulosin oral controlled absorption system (OCAS) 0.4 mg; solifenacin 3, 6, or 9 mg; solifenacin 3, 6 or 9 mg plus tamsulosin OCAS 0.4 mg; or placebo.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FP - Other medical fields
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)